Immutep ( (IMMP) ) has provided an announcement.
On May 5, 2025, Immutep announced promising results from its Phase IIb trial of eftilagimod alfa (efti) combined with KEYTRUDA® (pembrolizumab) for treating head and neck cancer patients with PD-L1 CPS <1. The trial showed a median overall survival of 17.6 months, significantly improving upon existing treatments. This development highlights a potential breakthrough for patients with high unmet medical needs, as current therapies involve chemotherapy. The company plans to meet with the FDA to discuss approval pathways, underscoring the combination's potential impact on treatment options and Immutep's positioning in the immunotherapy market.
Spark’s Take on IMMP Stock
According to Spark, TipRanks’ AI Analyst, IMMP is a Neutral.
Immutep’s overall score reflects significant financial and operational challenges common in early-stage biotech firms. The stable balance sheet and ability to secure financing are positive factors, but ongoing losses and cash flow issues impact the score. Technical analysis indicates mixed market sentiment, while valuation remains unattractive due to negative earnings. The absence of earnings call insights or corporate events leaves the outlook uncertain, emphasizing the need for successful product development and commercialization.
To see Spark’s full report on IMMP stock, click here.
More about Immutep
Immutep is a late-stage biotechnology company focused on developing novel immunotherapies for cancer and autoimmune diseases. The company is a leader in the research and development of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), leveraging its expertise to create innovative treatment options and maximize shareholder value.
YTD Price Performance: 12.67%
Average Trading Volume: 234,771
Technical Sentiment Signal: Sell
Current Market Cap: $254.2M
Learn more about IMMP stock on TipRanks’ Stock Analysis page.